KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Cash from Financing Activities (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Cash from Financing Activities for 6 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 91.8% year-over-year to -$1.9 million, compared with a TTM value of -$106.1 million through Dec 2025, down 116.15%, and an annual FY2025 reading of -$106.1 million, down 116.15% over the prior year.
  • Cash from Financing Activities was -$1.9 million for Q4 2025 at Aurinia Pharmaceuticals, up from -$10.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $205.7 million in Q4 2021 and bottomed at -$49.3 million in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $3.3 million, with a median of -$1.9 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities soared 304.69% in 2023, then plummeted 1018.3% in 2024.
  • Year by year, Cash from Financing Activities stood at $205.7 million in 2021, then crashed by 99.67% to $688000.0 in 2022, then plummeted by 910.61% to -$5.6 million in 2023, then plummeted by 313.23% to -$23.0 million in 2024, then skyrocketed by 91.8% to -$1.9 million in 2025.
  • Business Quant data shows Cash from Financing Activities for AUPH at -$1.9 million in Q4 2025, -$10.5 million in Q3 2025, and -$44.4 million in Q2 2025.